MG
LYRA

Michael Gelband’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Michael Gelband’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,185
Closed -$41K – 1818
2024
Q3 		$41K Buy
+3,185
New +$46.8K ﹤0.01% 1547
2024
Q2 		– Sell
-642
Closed -$200K – 1786
2024
Q1 		$200K Buy
642
+61
+10% +$16.3K ﹤0.01% 1355
2023
Q4 		$152K Buy
+581
New +$105K ﹤0.01% 1317
2021
Q3 		– Sell
-631
Closed -$253K – 2418
2021
Q2 		$253K Buy
+631
New +$287K ﹤0.01% 1840
2020
Q3 		– Sell
-1,670
Closed -$947K – 2030
2020
Q2 		$947K Buy
+1,670
New +$1.22M 0.02% 772

Other funds holding LYRA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Michael Gelband's LYRA Position: Q4 2024 in Review

Michael Gelband sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2024, closing a stake of 3,185 shares — an estimated $41K sold.

Michael Gelband first reported a position in LYRA in Q2 2020 and held it in 5 quarters. The position peaked at $947K in Q2 2020. 54 funds tracked by Wall St. Rank hold LYRA as of Q4 2024.

  • Michael Gelband reported no remaining LYRA THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 3,185 LYRA THERAPEUTICS INC shares in Q4 2024, an estimated $41K.
  • Michael Gelband first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 5 quarters.
  • Michael Gelband's LYRA THERAPEUTICS INC position peaked at $947K in Q2 2020.
  • 54 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.